Physicians already know a great deal about Sjögren’s syndrome’s symptoms and potential complications, and a new study confirms data on two long-suspected predictors of progression (i.e., measurable phenotypic findings) that could show which patients are likely to progress to active disease: hypergammaglobulinemia and hypocomplementemia. Published in the February issue of Arthritis Care & Research, “Natural…
![](https://www.the-rheumatologist.org/wp-content/uploads/2018/10/THR_1018_pg100a-150x150.png)